Patrick MERCIÉ

:Journées des Professionnels de Santé@univbordeaux@CHUBordeauxJPS26 formation continue en santé le jeudi 26 février 2026 au collège des sciences de la santé à@SanteCollege : Lien de présentation 🔗

💬 Editorial: Statin guidelines and patient preferences for #ASCVD prevention often misalign, supporting the need for clearer risk communication and shared decision-making in clinical practice. ja.ma/4ckSECM

@docisa33 Pas fréquent en effet ! 😊

myélinolyse centropontine 😏

📰 Expérimentation biomédicale et respect de l’animal (SPS 355) Un article de Georges Chapouthier, en accès libre (et 🔊Audio-dispo ⚠️) sur afis.org/Experimentatio…

📚"L’intégrité scientifique - Sociologie des bonnes pratiques", de Michel Dubois, Catherine Guaspare (Presses universitaires de France, 2025, 424 pages, 21,00 €) Une note de lecture d'Hervé Maisonneuve, librement accessible sur afis.org/L-integrite-sc…

Fatigue, muscle fatigability, and the Hallmarks of Aging: a narrative review sciencedirect.com/science/articl…

📰 Contrôle (épi)génétique du déterminisme du sexe : le fer a son mot à dire (SPS 354) Un article de Christophe de la Roche Saint André, en accès libre (et 🔊Audio-dispo ⚠️) sur afis.org/Controle-epi-g…

Exercise-Induced Protein Lactylation: From Molecular Mechanisms to Precision Health Applications sciencedirect.com/science/articl…

A recent study evaluated how well the new 2022 ACR/EULAR classification criteria perform for diagnosing #ANCA-associated #vasculitis (AAV) — specifically granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) — in a large #pediatric cohort of 574 patients from the ARChiVe registry (A Registry of Childhood Vasculitis): ◦ The 2022 ACR/EULAR criteria classified more patients overall as having GPA or MPA (396 vs. 360 with pediatric-adapted European Medicines Agency [Ped-EMA] algorithm). ◦ They classified fewer as GPA (261 vs. 288) but more as MPA (135 vs. 72). ◦ There was less overlap (co-classification) between GPA and MPA with the new criteria (12% vs. 28%). ◦ The new criteria identified more statistically significant differences in clinical features between GPA and MPA (14 vs. 10 features using Pediatric Vasculitis Activity Score — PVAS). ◦ Performance for GPA classification (compared to physician's-diagnosis): - Sensitivity: Comparable (74.5% for ACR/EULAR vs. 72.1% for Ankara criteria). - Specificity: Clearly improved (93.9% for ACR/EULAR vs. 79.9% for Ankara criteria). This study supports the preferential use of the 2022 ACR/EULAR criteria over the older Ankara criteria for classifying GPA in pediatric patients. These criteria appear effective and more refined for use in childhood AAV. *Cabral DA, Bosman ES, McPhate N, et al; for the ARChiVe Investigators Network within the PedVas Initiative. Effective performance of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for antineutrophil-cytoplasmic-antibody-associated vasculitis in pediatric patients: an ARChiVe Study. Arthritis Rheumatol. Published online April 9, 2026. 🔗doi.org/10.1002/art.70…

A computer simulation found #ApoB-guided intensification of lipid-lowering therapy provides the most QALYs and is highly cost-effective compared to #LDL-C or #nonHDL-C targets. ja.ma/4tDsxwm

Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results and Research Summary: nejm.org/doi/full/10.10…

The way our immune cells age differs substantially by sex, from single-cell analysis of ~1,000 people. Implications for propensity for autoimmune diseases (women), vulnerability to cancer (men), immunosenescence and inflammaging @NatureAging nature.com/articles/s4358…

📰 "Écarts de richesse et mortalité aux États-Unis et en Europe" (SPS 354) Un article d'Alexandre Pariente, accessible gratuitement (et dispo en audio) sur afis.org/Ecarts-de-rich…

📰 Le doute est la clé de toute connaissance (SPS 355) Un article de Jacques Robert, Jérôme Barrière et Frédéric Delom, en accès libre (et 🔊Audio-dispo ⚠️) sur afis.org/Le-doute-est-l…

📢 L’Université populaire de la rationalité et de l’esprit critique (Sps 354) Ce cycle de conférences proposé par le sociologue Gérald Bronner et ses invités, explore les enjeux contemporains de la pensée critique. afis.org/L-Universite-p…

👉 HDL and ASCVD: is high HDL-C protective, harmful, or simply misleading? 👆 HDL is biologically complex and multifunctional — lipid transport, immune modulation, endothelial signaling 👆 HDL-C reflects cholesterol content, not biological function → surrogate, not mechanism 📍 Observational epidemiology: Reports U-shaped associations between HDL-C and mortality However: Highly prone to confounding and reverse causation Driven by comorbidities (liver disease, alcohol, inflammation, frailty) → Not suitable to infer causality 📍 Causality hierarchy matters: Mendelian randomization (MR): No consistent causal protection from HDL-C Strong causal signal for ApoB-containing lipoproteins → Genetic evidence overrides observational noise 📍 Interventional trials: Raising HDL-C → no reduction in ASCVD events CETP inhibition: benefits align with ApoB lowering, not HDL-C increase 📍 Mechanistic paradigm shift: From HDL quantity → HDL function Key metric: cholesterol efflux capacity (CEC) 📍 Clinical implications: High HDL-C ≠ protective Very high HDL-C should not reassure 📍 Focus remains on: ApoB / LDL-C Lp(a) Non-HDL-C 👆 Take-home: U-shaped HDL curves are epidemiology, not biology Reverse causation ≠ protection If it’s not causal, it’s not a target HDL-C is a marker. ApoB is the mechanism. 🔓 Open Access journals.lww.com/co-lipidology/… @society_eas @JohnKastelein @CO_Lipidology

La troublante question des faux souvenirs (SPS 354) Un article de Brigitte Axelrad, accessible gratuitement (et dispo en audio) sur afis.org/La-troublante-…

A new article summarizes the epidemiology, diagnosis, and management of celiac disease and highlights serologic testing, biopsy confirmation, associated autoimmune conditions, and a gluten-free diet as treatment. Read the Clinical Practice article “Celiac Disease” by Joseph A. Murray, MD, and Steffen Husby, MD, DMSc, from @mayoclinic and the University of Southern Denmark: nejm.org/doi/full/10.10…

NEW REVIEW—Glucocorticoid treatment in patients with inflammatory rheumatic diseases: current practice and open questions bit.ly/3PP9xwD @FraButtgereit @LaiShanTam3

📰 Du minéral au vivant - Sur Terre, la vie devait apparaître Un ouvrage de Michel Galiana-Mingot (EDP Sciences, 2025, 268 pages, 21 €) Note de lecture de Kevin Moris : afis.org/Du-mineral-au-…